https://scholars.lib.ntu.edu.tw/handle/123456789/494557
標題: | Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma | 作者: | Chiu H.-H. Tsai I.-L. YEN-SHEN LU CHING-HUNG LIN CHING-HUA KUO |
公開日期: | 2017 | 出版社: | Springer Verlag | 卷: | 409 | 期: | 28 | 起(迄)頁: | 6583-6593 | 來源出版物: | Analytical and Bioanalytical Chemistry | 摘要: | Biopharmaceutical products such as protein drugs and monoclonal antibodies (mAb) are currently of great interest with monoclonal antibody drugs being one of the fastest growing categories of biopharmaceutical products. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has gained high interest for measuring mAb drugs in biological samples in recent years due to its high selectivity. Bevacizumab is a humanized immunoglobulin G (IgG) mAb drug against human vascular endothelial cell growth factor A (VEGF-A). It is used for treating many types of cancers. Recent studies have indicated that clinical outcomes vary among patients treated with bevacizumab and produce various side effects, such as vascular disorders. In this study, we developed an LC-MS/MS method to quantify bevacizumab concentration. We selected readily available and economic materials for sample preparation to facilitate its wider use in clinical fields.—Protein G was used to trap bevacizumab from human plasma. In place of an extended stable isotope-labeled internal standard (SIL-IS), the IgG-based drug-IS tocilizumab was used because of its better calibration performance. The method was validated in terms of its precision, accuracy, linearity, and sensitivity. The accuracies which were expressed as percentage recoveries for three concentration levels were within 92.8?±?3.2 to 112.7?±?4.5%. Repeatability and intermediate precision in terms of peak area ratios were lower than 5.2 and 12.9% RSD, respectively. The application to patients’ sample measurements revealed a wide individual variability of drug concentrations, and the proposed simple and general method may facilitate personalized medicine for improving therapeutic efficacy and safety. [Figure not available: see fulltext.]. ? 2017, Springer-Verlag GmbH Germany. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030182345&doi=10.1007%2fs00216-017-0607-0&partnerID=40&md5=2f91da067966a952f83b0450f0e26d4d https://scholars.lib.ntu.edu.tw/handle/123456789/494557 |
ISSN: | 1618-2642 | DOI: | 10.1007/s00216-017-0607-0 | SDG/關鍵字: | Drug interactions; Endothelial cells; Liquid chromatography; Mass spectrometry; Monoclonal antibodies; Patient monitoring; Patient treatment; Plasma (human); Plasmas; Proteins; Purification; Bevacizumab; In-solution digestions; LC-MS/MS; Monoclonal antibodies (mAb); Protein G; Antibodies; bacterial protein; bevacizumab; IgG Fc-binding protein, Streptococcus; immobilized protein; immunological antineoplastic agent; blood; chemistry; high performance liquid chromatography; human; isolation and purification; limit of detection; magnet; procedures; tandem mass spectrometry; validation study; Antineoplastic Agents, Immunological; Bacterial Proteins; Bevacizumab; Chromatography, High Pressure Liquid; Humans; Immobilized Proteins; Limit of Detection; Magnets; Tandem Mass Spectrometry |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。